Breo Ellipta 100/25 mcg

Description

Breo Ellipta 100/25 mcg
(Fluticasone Furoate 100 mcg / Vilanterol 25 mcg)

Description:
Breo Ellipta 100/25 mcg is a once-daily inhalation medication used to treat chronic obstructive pulmonary disease (COPD) and asthma in adults. It combines fluticasone furoate, a corticosteroid that reduces inflammation in the airways, with vilanterol, a long-acting beta-agonist (LABA) that helps to relax the muscles around the airways. This combination works together to improve lung function, reduce symptoms, and help prevent exacerbations associated with asthma and COPD.

Breo Ellipta is designed for long-term maintenance treatment. It is not intended for the immediate relief of acute bronchospasm. The combination of anti-inflammatory action from fluticasone furoate and bronchodilation from vilanterol helps provide 24-hour relief from asthma and COPD symptoms such as wheezing, shortness of breath, coughing, and tightness in the chest.

Key Features:

• Dual-Action Therapy: Contains fluticasone furoate (100 mcg), a corticosteroid that reduces airway inflammation, and vilanterol (25 mcg), a LABA that dilates airways to make breathing easier.
• Once-Daily Dosing: Provides effective, 24-hour control with a single dose, taken once daily, making it easy to maintain treatment compliance.
• Asthma and COPD Treatment: Approved for the maintenance treatment of both asthma (in patients aged 18 years and older) and COPD, including chronic bronchitis and emphysema.
• Ellipta Inhaler Technology: The Ellipta inhaler is pre-loaded, ensuring accurate doses with every inhalation. It is easy to use and convenient, providing a hassle-free treatment experience for patients.
• 24-Hour Relief: The combination of fluticasone furoate and vilanterol offers continuous symptom control throughout the day and night, reducing flare-ups and helping patients manage chronic respiratory conditions.